FundedIQ
Biotechnology

Monte Rosa Therapeutics: Funding, Investors & Team (Sep 2026)

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

www.monterosatx.com LinkedIn Basel, Switzerland 51-100 employees
Biotechnology Therapeutics
Total raised
$95.0M
Rounds
1
Latest
Series C
Mar 2021

Monte Rosa Therapeutics has raised $95.0M across 1 funding round on record, the most recent a Series C of $95.0M announced in Mar 2021.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Monte Rosa Therapeutics Company Profile and Key Stats

Total funding raised
$95.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series C
$95.0M in Mar 2021
Employees
51-100
reported band
Headquarters
Basel, Switzerland

Latest funding round on record: Mar 2021.

Monte Rosa Therapeutics Funding Rounds

Date
Round
Amount
Series C
$95.0M

Monte Rosa Therapeutics Founders and Leadership Team

Name
Role
Contact
Markus Warmuth
CEO
Locked

Contact details for the Monte Rosa Therapeutics team: 1 of 1 has an email address on file.

Start 14-day free trial →

Monte Rosa Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
879
$3.8M
1,814
$58M

Monte Rosa Therapeutics' latest round of $95.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Monte Rosa Therapeutics in Biotechnology and Basel

Companies Similar to Monte Rosa Therapeutics

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…

Series A $40.0M

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…

Pre-Seed $3.0M

compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…

Undisclosed round $1.2M

MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…

Undisclosed round $200M

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…

Undisclosed round $490k

Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…

Pre-Seed $120k

Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…

Undisclosed round $1.1M

AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…

Undisclosed round $4.0M

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…

Undisclosed round $1.2M

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…

Undisclosed round $1.4M

MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…

Undisclosed round $10.2M

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…

Seed $7.5M

Monte Rosa Therapeutics Funding FAQs

What does Monte Rosa Therapeutics do?

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

How much funding has Monte Rosa Therapeutics raised?

Monte Rosa Therapeutics has raised $95.0M across 1 round on record. The most recent is a Series C of $95.0M announced in Mar 2021.

When did Monte Rosa Therapeutics last raise funding?

Monte Rosa Therapeutics' most recent funding round on record is a Series C of $95.0M, announced in Mar 2021.

Who is the CEO of Monte Rosa Therapeutics?

Markus Warmuth is listed as CEO at Monte Rosa Therapeutics.

Where is Monte Rosa Therapeutics headquartered?

Monte Rosa Therapeutics is based in Basel, Basel-Stadt, Switzerland.

How many employees does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics is in the 51-100 employee band.

How does Monte Rosa Therapeutics' funding compare to other Biotechnology startups?

Monte Rosa Therapeutics' latest round of $95.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Monte Rosa Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Monte Rosa Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.